Neoadjuvant Chemoimmunotherapy with Low-Dose Radiotherapy for Advanced Oral Cancer

This Phase II clinical trial investigates a promising new treatment approach for patients with locally advanced oral squamous cell carcinoma (OSCC) (stages III, IVA, and IVB). The study combines low-dose radiation therapy with chemotherapy and immunotherapy before surgery, potentially offering better outcomes while preserving oral function.

Treatment Approach: Patients receive:

• 2 cycles of combined chemotherapy (albumin paclitaxel and cisplatin) with immunotherapy (trastuzumab)
• Very low-dose radiation (1 Gy per session) delivered during chemotherapy days, totaling 4 Gy
• Surgical removal of the tumor about 4 weeks after completing neoadjuvant therapy
• Personalized postoperative treatment based on surgical results

Key Benefits Being Studied:

1. Complete tumor disappearance (pCR rate): Measuring how often tumors completely disappear before surgery
2. Organ preservation: Potential to maintain better oral function compared to standard treatments
3. Long-term survival: Tracking 2-year survival and cancer recurrence rates

Why This Matters: Oral cancer treatment often requires extensive surgery and high-dose radiation that can significantly impact quality of life. This study explores whether adding immunotherapy to lower doses of radiation and chemotherapy can:

• Shrink tumors effectively before surgery
• Reduce treatment side effects
• Improve long-term survival
• Preserve speaking, swallowing, and chewing abilities

Patient Considerations: The trial is for adults (18-70) with newly diagnosed, operable oral cancer who haven't had previous cancer treatments. Patients must have adequate organ function and be generally healthy aside from their cancer diagnosis. The study excludes those with certain medical conditions or active infections.

Understanding the Risks: Like all cancer treatments, this approach may cause side effects including:

• Chemotherapy-related nausea, fatigue, and blood count changes
• Potential immune-related reactions
• Surgical risks
• Radiation side effects (though at much lower doses than typical)

Future Implications: If successful, this treatment strategy could establish a new standard of care for locally advanced oral cancers, offering patients better outcomes with fewer long-term complications. The study also contributes valuable data about combining immunotherapy with radiotherapy, which may apply to other cancer types.

For Caregivers: This treatment approach may require:

• Multiple hospital visits for therapy sessions
• Close monitoring for side effects
• Support during recovery from surgery
• Help managing daily activities during treatment periods

The research team will carefully track each patient's response and adjust follow-up care accordingly, focusing on both cancer control and quality of life outcomes.